Adjust Font Size: Decrease Increase

News

November 3, 2014 — Micell Technologies, Inc. today announced commercialization plans for its MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent.
Read more.
September 16, 2014 — Micell Technologies Highlights Positive Three-Year Data from MiStent SES DESSOLVE Clinical Studies at TCT 2014
Read more.
July 9, 2014 — Micell Technologies Adds to Portfolio of Intellectual Property Protection
Read more.
May 23, 2014 — Micell Technologies Announces Positive Long-Term Data from MiStent SES Clinical Studies Presented at EuroPCR 2014
Read more.
May 15, 2014 — Micell Technologies Announces Clinical Data from MiStent SES Studies Will Be Presented at EuroPCR 2014
Read more.
March 5, 2014 — Long-Term Safety and Efficacy of MiStent SES Presented at CRT 2014
Read more.
November 21, 2013 — Paper Published in American Journal of Cardiology Demonstrates Favorable Vascular Healing Following MiStent SES Implantation
Read more.
October 28, 2013 — MiStent SES Shown to be Unique in Clinical Setting
Read more.
October 1, 2013 — Micell Technologies Announces Development and Distribution Agreement to Bring MiStent SES to China
Read more.
September 30, 2013 — Micell Technologies Announces DESSOLVE I Manuscript Accepted for Publication in American College of Cardiology’s Cardiovascular Interventions Journal
Read more.
June 12, 2013 — Micell Technologies Receives CE Mark Approval for MiStent SES
Read more.
November 6, 2012 — Micell Technologies Announces Issuance of Core Technology Patent
Read more.
October 23 2012 — Micell Technologies Announces Positive Data from Clinical Studies of MiStent SES
Read more.
October 16, 2012 — Micell Technologies Announces Clinical Data Presentations at TCT 2012
Read more.
November 8, 2011 — Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System
Read more.
November 2, 2011 — Micell Technologies Announces Presentation of Clinical Data at TCT 2011
Read more.
July 26, 2011 — Micell Technologies Completes Enrollment in DESSOLVE II Study of the MiStent® Drug-Eluting Coronary Stent
Read more.
June 29, 2011 — Micell Technologies Announces Reduced Clinical Trial Sample Size for MiStent® Drug-Eluting Coronary Stent Based on Early Clinical Data
Read more.
May 11, 2011 — Micell Technologies Reports Preclinical Data for MiStentTM Drug-Eluting Coronary Stent to be Presented at EuroPCR
Read more.
February 17, 2011 — Micell Technologies Enrolls First Patient in CE Mark DESSOLVE II Study of MiStentTM Drug-Eluting Coronary Stent (DES)
Read more.
November 29, 2010 — Micell Technologies Enrolls First Patient in DESSOLVE I First-In-Human Study of MiStent DES.
Read more.
September 21, 2009 — Micell Receives $15 Million Equity Investment.
Read more.
March 4, 2009 — The Micell Rapid Absorption Polymer DES System to be Presented at CRT 2009.
Read more.
January 12, 2009 — Micell Forges Strategic Agreement to Develop Advanced Drug-eluting Stents and Balloons.
Read more.
Caution: The MiStent SES has received CE marking but is not approved in the USA or any other countries. Any other products described on this website are investigational devices that are not available for sale in any country.
Home | About Us | Therapeutic Focus | Product Pipeline | Technology | News | Terms of Use | Privacy Policy | Site Map
© 2014 Micell Technologies, Inc. All rights reserved.
"Micell", "MiStent", and "MiStent SES" are registered trademarks of Micell Technologies, Inc.